Loading organizations...
Key people at Genesys Capital.
Genesys Capital was founded in 2000 by Damian Lamb (Co-Founder and Managing Director) and Kelly Holman (Co-Founder and Managing Director).
Genesys Capital is a life sciences venture capital firm that primarily invests in early-stage biotechnology and medical innovation companies to fund clinical development. The firm focuses on addressing unmet medical needs by deploying institutional capital and providing strategic operational support to its portfolio, acting as the lead founding investor in approximately 80% of its transactions. Across five distinct early-stage venture capital funds, the organization has successfully raised over $400 million in total capital commitments and invested in 44 different enterprises within the healthcare sector. The firm has realized a total of 20 exits to date, highlighted by the strategic acquisitions of portfolio companies Fusion Pharmaceuticals by AstraZeneca, as well as Affinium Pharmaceuticals by Debiopharm. Genesys Capital was officially established as an investment vehicle in the year 2000 by co-founders Kelly Holman and Damian Lamb.
Genesys Capital was founded in 2000 by Damian Lamb (Co-Founder and Managing Director) and Kelly Holman (Co-Founder and Managing Director).
Key people at Genesys Capital.
Genesys Capital has 17 tracked investments across 10 companies. The latest tracked deal is $24.0M Other Equity in Veralox Therapeutics in June 2023.
